Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 2/2013

01-02-2013 | Adis Drug Evaluation

Iobitridol

A Review of Its Use as a Contrast Medium in Diagnostic Imaging

Author: Paul L. McCormack

Published in: Clinical Drug Investigation | Issue 2/2013

Login to get access

Abstract

Iobitridol is a water-soluble, non-ionic, monomeric, low-osmolar, iodine-based contrast medium in which the potential for interaction with membrane proteins in the body has been minimized by stable masking of the molecule’s lipophilic tri-iodinated benzene ring. It is approved in various countries worldwide for use as an intravascular contrast medium in adults and children. This article reviews the diagnostic efficacy and tolerability of iobitridol use as an intravascular contrast agent in diagnostic imaging, and briefly overviews its pharmacological properties. In randomized controlled trials, the global image quality and diagnostic quality with iobitridol did not differ from those with other low-osmolar contrast media (iohexol, iopromide, iopamidol, iomeprol and ioxaglate) or the iso-osmolar contrast medium iodixanol in adults or children undergoing radiographic imaging. Large post-marketing surveillance studies have confirmed that iobitridol produces good or excellent opacification and is an effective contrast agent in the vast majority of patients. Iobitridol was generally well tolerated and had a tolerability profile similar to that of other low-osmolar and iso-osmolar contrast media. Thus, iobitridol is an effective intravascular agent for contrast enhancement in diagnostic imaging.
Literature
1.
Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist. Mayo Clinic Proc. 2012;87(4):390–402.CrossRef
2.
Singh J, Daftary A. Iodinated contrast media and their adverse reactions. J Nucl Med Technol. 2008;36(2):69–74.PubMedCrossRef
3.
Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005;68(1):14–22.PubMedCrossRef
4.
Hein PA, May J, Rogalla P, et al. Feasibility of contrast material volume reduction in coronary artery imaging using 320-slice volume CT. Eur Radiol. 2010;20(6):1337–43.PubMedCrossRef
5.
Dewey M, Zimmermann E, Deissenrieder F, et al. Noninvasive coronary angiography by 320-row computed tomography with lower radiation exposure and maintained diagnostic accuracy: comparison of results with cardiac catheterization in a head-to-head pilot investigation. Circulation. 2009;120:867–75.PubMedCrossRef
6.
Bettmann MA. Intravascular contrast agents: current problems and future solutions: a review. Acta Radiol. 1996;37(Suppl. 400):3–7.
7.
Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media—a European multicenter study. Allergy. 2009;64(2):234–41.PubMedCrossRef
8.
Dewachter P, Laroche D, Mouton-Faivre C, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol. 2011;77(3):495–501.PubMedCrossRef
9.
Kvedariene V, Martins P, Rouanet L, et al. Diagnosis of iodinated contrast media hypersensitivity: results of a 6-year period. Clin Exp Allergy. 2006;36(8):1072–7.PubMedCrossRef
10.
Maurer M, Heine O, Wolf M, et al. Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients. Eur J Radiol. 2011;80(2):357–62.PubMedCrossRef
11.
Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527–41.PubMedCrossRef
12.
Meyer D, Petta M, Fouchet MH, et al. Stabilization of the hydrophilic sphere of iobitridol, a new nonionic iodinated contrast agent. Acta Radiol. 1996;37(Suppl. 400):8–16.
13.
Idée JM, Balut C, Beaufils H, et al. Pharmacologic profile of iobitridol, a nonionic iodinated contrast medium. Acta Radiol. 1996;37(Suppl. 400):35–48.
14.
Violon D. Application of the lateral/facial protection model to a new molecule, iobitridol. Invest Radiol. 1996;31(10):668–70.PubMedCrossRef
15.
16.
17.
18.
Prangé T, Neuman A, Corot C, et al. Study of the complex between the contrast agent iobitridol (Xenetix) and elastase (PPE): a model for hydrophobic site protection in drug-protein interactions. Pharm Res. 1997;14(12):1713–7.PubMedCrossRef
19.
Donadieu AM, Idée JM, Doucet D, et al. Toxicologic profile of iobitridol, a new nonionic low-osmolality contrast medium. Acta Radiol. 1996;37(Suppl. 400):17–24.
20.
Wasaki M, Kawamura H, Sugimoto J, et al. Comparative toxic effects of iobitridol and iohexol on the kidney. Invest Radiol. 1998;33(7):393–400.PubMedCrossRef
21.
Beaufils H, Idée JM, Berthommier C, et al. Iobitridol, a new nonionic low-osmolality contrast agent, and iohexol: impact on renal histology in the rat. Invest Radiol. 1995;30(1):33–9.PubMedCrossRef
22.
Larras-Regard E, Mony M-C. Intracellular imaging of iodinated contrast media in rat kidney by SIMS (IMS 4F). In: Lareau R, Gilled D, editors. The secondary ion mass spectrometry, SIMS XI. New York: Wiley; 1998. p. 135–8.
23.
Bach R, Gerk U, Mrowietz C, et al. Influence of a new monomeric nonionic radiographic contrast medium (iobitridol-350 versus NaCl) on cutaneous microcirculation: single-center, prospective, randomized, double-blind phase IV study in parallel group design. Microvasc Res. 2000;60(3):193–200.PubMedCrossRef
24.
Rouleau P, Alison D, Bertrand P, et al. Time course of biodistribution and changes in density following administration of iobitridol in rabbits: a comparative study vs iohexol. Acta Radiol. 1996;37(Suppl. 400):49–55.
25.
Bourrinet P, Dencausse A, Cochet P, et al. Whole body quantitative autoradiographic study of the biodistribution of iobitridol in rats. Invest Radiol. 1994;29(12):1057–60.PubMedCrossRef
26.
Bourrinet P, Dencausse A, Havard P, et al. Transplacental passage and milk excretion of iobitridol. Invest Radiol. 1995;30(3):156–8.PubMedCrossRef
27.
Dencausse A, Violas X, Feldman H, et al. Pharmacokinetic profile of iobitridol. Acta Radiol. 1996;37(Suppl. 400):25–34.
28.
Guerbet. Xenetix 350 (iobitridol 350 mg I/mL), solution for injection: summary of product characteristics (UK). Roissy CdG Cedex: Guerbet; 2002.
29.
Bouard JC, Lyonnet D, Illes JP, et al. Clinical experience with iobitridol 250–300 in digital subtraction angiography: double-blind randomized studies vs iopromide and iohexol. Acta Radiol. 1996;37(Suppl. 400):85–8.
30.
Fournier PJ, Steinbrich W, Freitag P, et al. Evaluation of the clinical safety and efficacy of iobitridol (Xenetix) in intravenous urography. Eur J Radiol. 1996;23(3):185–9.PubMedCrossRef
31.
Hoogewoud HM, Woessmer B. Iobitridol 300 compared to iopromide 300: a double-blind randomized phase-III study of clinical tolerance in total body CT. Acta Radiol. 1996;37(Suppl. 400):62–4.
32.
Legmann P, Vignaux O, Bahurel H, et al. Hepatic and vascular enhancement at dual-phase helical CT: comparison of iobitridol 300 and iohexol 300 in a prospective randomized study. Eur Radiol. 2001;11(11):2220–7.PubMedCrossRef
33.
Taylor W, Moseley I. Assessment of the safety and efficacy of iobitridol, an iodinated contrast medium (30% iodine), in cranial CT. Eur J Radiol. 1995;20(1):57–60.PubMedCrossRef
34.
Stockx L, Wilms G, Baert AL, et al. Clinical tolerance and diagnostic efficacy of iobitridol 300 in lower limb angiography. Acta Radiol. 1996;37(Suppl. 400):72–4.
35.
Chagnaud C, Moulin G, Bartoli JM, et al. Iobitridol 250 vs iohexol 240 in phlebography of the lower limbs: a double-blind clinical trial. Acta Radiol. 1996;37(Suppl. 400):89–91.
36.
Drouillard J, Froment JC, Frija G, et al. Efficacy and safety of iobitridol versus iohexol for contrast-enhanced CT of the head. Acta Radiol. 1996;37(Suppl. 400):56–61.
37.
Lefèvre T, Funck F, Aliot E, et al. Safety and efficacy of the new iodinated nonionic low-osmolality contrast medium iobitridol (Xenetix) in coronary and ventricular angiography. Acta Radiol. 1996;37(Suppl. 400):75–80.
38.
Loewe C, Becker CR, Berletti R, et al. 64-Slice CT angiography of the abdominal aorta and abdominal arteries: comparison of the diagnostic efficacy of iobitridol 350 mgI/ml versus iomeprol 400 mgI/ml in a prospective, randomised, double-blind multi-centre trial. Eur Radiol. 2010;20(3):572–83.PubMedCrossRef
39.
Meiss L, Bakker AJ, Falke TH, et al. Clinical safety and efficacy of iobitridol in urography. Acta Radiol. 1996;37(Suppl. 400):68–71.
40.
Rossignol AM, Lusson JR, Chantepie A, et al. Safety and efficacy of Xenetix, a new iodinated contrast agent, in pediatric angiocardiography. Acta Radiol. 1996;37(Suppl. 400):81–4.
41.
Smets A, Shaw D. Clinical tolerance and diagnostic efficacy of iobitridol in contrast-enhanced CT in children. Acta Radiol. 1996;37(Suppl. 400):65–7.
42.
Velázquez MT, Albarrán A, Hernández F, et al. Less iodine injected for the same diagnostic performances: comparison of two low-osmolar contrast agents (iobitridol 350 and iopamidol 370) in coronary angiography and ventriculography: a randomized double-blind clinical study. Acta Cardiol. 2010;65(4):387–94.PubMed
43.
Dieu V, Joffre F, Krause D, et al. A comparison of the efficacy and safety of ioxaglate and iobitridol in renal angioplasty. Cardiovasc Intervent Radiol. 2000;23(2):91–6.PubMedCrossRef
44.
Zo’o M, Hoermann M, Balassy C, et al. Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CT. Pediatr Radiol. 2011;41(11):1393–400.PubMedCrossRef
45.
Petersein J, Peters CR, Wolf M, et al. Results of the safety and efficacy of iobitridol in more than 61,000 patients. Eur Radiol. 2003;13(8):2006–11.PubMedCrossRef
46.
Vogl TJ, Honold E, Wolf M, et al. Safety of iobitridol in the general population and at-risk patients. Eur Radiol. 2006;16(6):1288–97.PubMedCrossRef
47.
Wendt-Nordahl G, Rotert H, Trojan L, et al. Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients. Med Princ Pract. 2006;15(5):358–61.PubMedCrossRef
48.
Briguori C, Colombo A, Airoldi F, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int. 2005;68(5):2250–5.PubMedCrossRef
49.
Alexopoulos E, Spargias K, Kyrzopoulos S, et al. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. Am J Med Sci. 2010;339(1):25–30.PubMedCrossRef
50.
Vijayalakshmi K, Williams D, Wright RA, et al. A prospective, randomized trial to determine the early and late reactions after the use of iopamidol 340 (Niopam) and iobitridol 350 (Xenetix) in cardiac catheterization. J Invasive Cardiol. 2004;16(12):707–11.PubMed
51.
Ranucci M, Ballotta A, Kunkl A, et al. Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery. Am J Cardiol. 2008;101(8):1112–8.PubMedCrossRef
52.
Deray G, Bellin MF, Zaim S, et al. Evaluation of the renal tolerance of Xenetix in patients with chronic renal failure. Nephron. 1998;80(2):240.PubMedCrossRef
53.
Pinès E, Zamia P, Idèe J-M. In response to: K. Vijayalakshmi, et al, 16(12), pp. 707–711: A prospective, randomized trial to determine the early and late reactions after the use of iopamidol 340 (Niopam) and iobitridol 350 (Xenetix) in cardiac catheterization. J Invasive Cardiol. 2005;17(2):123–4.PubMed
54.
Gayet J-L, Lefèvre T. In response to: K. Vijayalakshmi, et al, 16(12), pp. 707–711: A prospective, randomized trial to determine the early and late reactions after the use of iopamidol 340 (Niopam) and iobitridol 350 (Xenetix) in cardiac catheterization. J Invasive Cardiol. 2005;17(2):124.PubMed
55.
Guerbet. Xenetix 300 (iobitridol 300 mg I/mL), solution for injection: summary of product characteristics (UK). Roissy CdG Cedex: Guerbet; 2002.
56.
Nivelle E, Mathou F, Lamotte M. Assessing the budget impact of using ScanBag® in CT in 6 European countries [abstract no. PMD 13]. International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting, Washington (DC); 2–6 Jun 2012.
57.
Schiesser P, Auclair P, Moro L, et al. Life cycle assessment of a new drug’s packaging: a key aspect in the health technology assessment of a drug? [abstract no. P-082]. EcoBalance, Tokyo; 9–12 Nov 2010.
58.
Guerbet. Xenetix 250 (iobitridol 250 mg I/mL), solution for injection: summary of product characteristics (UK). Roissy CdG Cedex: Guerbet; 2002.
59.
Thomsen HS, Morcos SK, ESUR Contrast Media Safety Committee. Management of acute adverse reactions to contrast media. Eur Radiol. 2004;14(3):476–81.PubMedCrossRef
60.
Bellin MF, Stacul F, Webb JAW, et al. Late adverse reactions to intravascular iodine based contrast media: an update. Eur Radiol. 2011;21:2305–10.PubMedCrossRef
61.
Schweiger MJ, Chambers CE, Davidson CJ, et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv. 2007;69(1):135–40.PubMedCrossRef
Metadata
Title
Iobitridol
A Review of Its Use as a Contrast Medium in Diagnostic Imaging
Author
Paul L. McCormack
Publication date
01-02-2013
Publisher
Springer International Publishing AG
Published in
Clinical Drug Investigation / Issue 2/2013
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-013-0055-3

Other articles of this Issue 2/2013

Clinical Drug Investigation 2/2013 Go to the issue

Original Research Article

Effect of Concomitant Administration of Trospium Chloride Extended Release on the Steady-State Pharmacokinetics of Metformin in Healthy Adults

Original Research Article

Study of the Population Pharmacokinetic Characteristics of Once-Daily Trospium Chloride 60 mg Extended-Release Capsules in Patients with Overactive Bladder and in Healthy Subjects

Original Research Article

Intravenous Bisphosphonates for Postmenopausal Osteoporosis: Safety Profiles of Zoledronic Acid and Ibandronate in Clinical Practice

Short Communication

Effect of Implantation of Augment® Bone Graft on Serum Concentrations of Platelet-Derived Growth Factors: A Pharmacokinetic Study

Review Article

Pharmacokinetic Profile of Liposome Bupivacaine Injection Following a Single Administration at the Surgical Site

Review Article

Improving Treatment Adherence in Your Patients with Schizophrenia